tiprankstipranks
Advertisement
Advertisement

IKT Stock Latest News

IKT Upcoming Earnings Report: What to Expect?
Pre-EarningsIKT Upcoming Earnings Report: What to Expect?
3d ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
23d ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
23d ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
PremiumRatings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
1M ago
IKT
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
PremiumMarket News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
1M ago
IKT
WVE
Inhibikase Therapeutics initiated with a Buy at BofA
PremiumThe FlyInhibikase Therapeutics initiated with a Buy at BofA
2M ago
IKT
Dynavax, Inhibikase and More: Stocks Trending by Analysts
Premium
Weekend Updates
Dynavax, Inhibikase and More: Stocks Trending by Analysts
3M ago
IKT
DVAX
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
Premium
Ratings
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
3M ago
IKT
Inhibikase Updates ATM Equity Program to Raise Capital
PremiumCompany Announcements
Inhibikase Updates ATM Equity Program to Raise Capital
3M ago
8K
IKT
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
4M ago
IKT
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
PremiumRatings
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
4M ago
IKT
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
4M ago
IKT
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
PremiumCompany AnnouncementsInhibikase Therapeutics Announces $93.6 Million Stock Offering
4M ago
8K
IKT
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
Premium
The Fly
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
4M ago
IKT
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
Premium
The Fly
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
4M ago
IKT
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
PremiumCompany Announcements
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
4M ago
8K
IKT
Inhibikase announces common stock and warrants offering, no amount given
PremiumThe Fly
Inhibikase announces common stock and warrants offering, no amount given
4M ago
IKT
Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
PremiumThe Fly
Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
4M ago
IKT
Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating
PremiumRatings
Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating
4M ago
IKT
Inhibikase Therapeutics: Strong Financial Position and Strategic Advancements Drive Buy Rating
PremiumRatingsInhibikase Therapeutics: Strong Financial Position and Strategic Advancements Drive Buy Rating
7M ago
IKT
Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer
Premium
The Fly
Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer
7M ago
IKT
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress
Premium
Company Announcements
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress
7M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >